Barclays lowered the firm’s price target on Kura Oncology (KURA) to $11 from $32 and keeps an Overweight rating on the shares post the Q1 report. The firm “de-risking” the model but says Kura’s key catalysts are on track.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology Advances with Key NDA Submission
- Kura Oncology: Promising Clinical Trial Results and Strong Financial Position Support Buy Rating
- Kura Oncology’s Promising Future: Strong Financial Health and Successful Clinical Trials Drive Buy Rating
- Kura Oncology reports Q1 EPS (66c), consensus (60c)
- Kura Oncology (KURA) Q1 Earnings Cheat Sheet
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue